Trials / Active Not Recruiting
Active Not RecruitingNCT06396039
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
A Phase 4, Multicenter, Single-arm, Open-label Study to Evaluate the Effectiveness and Safety of Oral Ozanimod for Relapsing Multiple Sclerosis (RMS) in Chinese Participants
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effectiveness and safety of ozanimod in Chinese adults with relapsing multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986374 | Specified dose on specified days. |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2028-12-29
- Completion
- 2029-03-30
- First posted
- 2024-05-02
- Last updated
- 2025-04-16
Locations
25 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06396039. Inclusion in this directory is not an endorsement.